By Colin Kellaher Spero Therapeutics has named Esther Rajavelu chief financial and business officer of the clinical-stage biopharmaceutical company. The.
Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Free Report) shares crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.53 and traded as low as $1.12. Spero Therapeutics shares last traded at $1.15, with a volume of 78,492 shares. Analyst Ratings Changes Separately, HC Wainwright reiterated […]
Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Free Report) was the target of a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 1,430,000 shares, an increase of 25.4% from the August 31st total of 1,140,000 shares. Based on an average trading volume of 336,400 shares, […]
HC Wainwright reaffirmed their buy rating on shares of Spero Therapeutics (NASDAQ:SPRO – Free Report) in a research report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock. Spero Therapeutics Trading Up 1.5 % NASDAQ SPRO opened at $1.36 on Tuesday. Spero Therapeutics has a fifty-two week […]
Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) – Research analysts at HC Wainwright reduced their Q4 2023 EPS estimates for shares of Spero Therapeutics in a research note issued to investors on Monday, August 14th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.50 for the quarter, […]